Transferrin decorated PLGA encumbered moxifloxacin nanoparticles and in�vitro cellular studies

Simple item page
dc.contributor.authorReddy, Gayathri Aparnasai
dc.contributor.authorHanda, Mayank
dc.contributor.authorGarabadu, Debapriya
dc.contributor.authorKumar, Ravindra
dc.contributor.authorKushawaha, Pramod Kumar
dc.contributor.authorShukla, Rahul
dc.date.accessioned2024-01-21T10:55:10Z
dc.date.accessioned2024-08-14T07:44:24Z
dc.date.available2024-01-21T10:55:10Z
dc.date.available2024-08-14T07:44:24Z
dc.date.issued2023-03-05T00:00:00
dc.description.abstractPurpose: Complicated intra-abdominal infection (cIAI) management involves administering antibiotics that destroy the cell wall and the genesis of bacterial lipopolysaccharide (LPS). During the infectious state, the expression of transferrin receptors upregulates on the intestinal epithelial cells, which are considered the site of infection. In the present research, transferrin decorated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulated moxifloxacin (MOX) were developed for possible targeting of the receptors in the colon. Significance: This study will explore more about the incorporation of transferrin as effective coating material in targeted drug delivery. Methods: Nanoparticles were prepared using nano-emulsification and surface modification with transferrin was done by layer-by-layer methodology and evaluated by powder X-ray diffraction (PXRD), differential scanning calorimeter (DSC), FTIR, SEM, antibacterial activity, and cellular uptake studies. Results: The formulated NPs exhibit a size of ?170 nm, PDI�?�0.25, zeta potential�??4.0 mV, drug loading�?�6.8%, and entrapment efficiency of 82%. Transferrin-decorated NPs exhibit tailored release for almost 12 h and in�vitro antibacterial activity for 14 h. The cellular uptake studies were done on a RAW264.7 cell line for better determination of transferrin uptake of fabricated NPs. Conclusion: The above study circumvents around the preparation of transferrin decorated PLGA encumbered MOX NPs intended for cIAI-induced sepsis. PLGA NPs provide tailored release of MOX with primary burst and followed by sustained release. These observations confines with antibacterial activity studies. The prepared transferrin-coated NPs were stable and effectively uptaken by RAW264.7 cells. However, future studies include the preclinical investigation of these NPs in sepsis-induced murine models. � 2023 Informa UK Limited, trading as Taylor & Francis Group.en_US
dc.identifier.doi10.1080/03639045.2023.2185463
dc.identifier.issn3639045
dc.identifier.urihttp://10.2.3.109/handle/32116/4361
dc.identifier.urlhttps://www.tandfonline.com/doi/full/10.1080/03639045.2023.2185463
dc.language.isoen_USen_US
dc.publisherTaylor and Francis Ltd.en_US
dc.subjectIBDen_US
dc.subjectmoxifloxacinen_US
dc.subjectnanoparticlesen_US
dc.subjectPLGAen_US
dc.subjectsepsisen_US
dc.subjectTransferrinen_US
dc.titleTransferrin decorated PLGA encumbered moxifloxacin nanoparticles and in�vitro cellular studiesen_US
dc.title.journalDrug Development and Industrial Pharmacyen_US
dc.typeArticleen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Pharmacology - Research Publications